EA201001357A1 - Слитые конструкции и конъюгаты лекарственного средства - Google Patents

Слитые конструкции и конъюгаты лекарственного средства

Info

Publication number
EA201001357A1
EA201001357A1 EA201001357A EA201001357A EA201001357A1 EA 201001357 A1 EA201001357 A1 EA 201001357A1 EA 201001357 A EA201001357 A EA 201001357A EA 201001357 A EA201001357 A EA 201001357A EA 201001357 A1 EA201001357 A1 EA 201001357A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugates
medicines
relates
fusion constructs
fused structures
Prior art date
Application number
EA201001357A
Other languages
English (en)
Other versions
EA018471B1 (ru
Inventor
Кристофер Херринг
Люси Дж. Хольт
Лоран Жеспер
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA201001357A1 publication Critical patent/EA201001357A1/ru
Publication of EA018471B1 publication Critical patent/EA018471B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)

Abstract

Настоящее изобретение относится к слитым конструкциям лекарственного средства, обладающим улучшенными периодами полувыведения из сыворотки. Эти слитые конструкции и конъюгаты содержат полипептиды, единичные вариабельные домены иммуноглобулинов (антител) и молекулы GLP (глюкагоноподобного пептида) и/или эксендина. Изобретение также относится к применению, препаратам, композициям и устройствам, содержащим такие слитые конструкции и конъюгаты лекарственного средства.Дозозависимое уменьшение массы тела в мышиной модели ожирения в результате введения DAT0115
EA201001357A 2008-03-31 2009-03-27 Слитые конструкции и конъюгаты лекарственного средства EA018471B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4079608P 2008-03-31 2008-03-31
US8689108P 2008-08-07 2008-08-07
PCT/EP2009/053640 WO2009121804A1 (en) 2008-03-31 2009-03-27 Drug fusions and conjugates

Publications (2)

Publication Number Publication Date
EA201001357A1 true EA201001357A1 (ru) 2011-04-29
EA018471B1 EA018471B1 (ru) 2013-08-30

Family

ID=40683717

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001357A EA018471B1 (ru) 2008-03-31 2009-03-27 Слитые конструкции и конъюгаты лекарственного средства

Country Status (13)

Country Link
US (2) US20110020345A1 (ru)
EP (1) EP2259802A1 (ru)
JP (1) JP2011517561A (ru)
KR (1) KR20100132535A (ru)
CN (1) CN102046207B (ru)
AU (1) AU2009231439A1 (ru)
BR (1) BRPI0909397A2 (ru)
CA (1) CA2718480A1 (ru)
EA (1) EA018471B1 (ru)
MX (1) MX2010010776A (ru)
SG (1) SG189682A1 (ru)
WO (1) WO2009121804A1 (ru)
ZA (1) ZA201006763B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010063818A2 (en) * 2008-12-05 2010-06-10 Glaxo Group Limited Methods for selecting protease resistant polypeptides
CA2756853A1 (en) * 2009-03-27 2010-09-30 Christopher Herring Drug fusions and conjugates
EP2483308A1 (en) * 2009-09-30 2012-08-08 Glaxo Group Limited Drug fusions and conjugates with extended half life
US9835416B1 (en) 2010-04-12 2017-12-05 The United States Of America, As Represented By The Secretary Of The Navy Multi-ply heterogeneous armor with viscoelastic layers
JP2013537421A (ja) * 2010-08-20 2013-10-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
CN106986940A (zh) * 2010-09-28 2017-07-28 艾米琳制药有限责任公司 具有增强的作用持续时间的工程化多肽
CN102010473A (zh) * 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
TWI689314B (zh) 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
WO2012136792A2 (en) * 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2012136790A1 (en) * 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
US9428749B2 (en) 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
WO2013138338A2 (en) 2012-03-12 2013-09-19 Massachusetts Institute Of Technology Methods for treating tissue damage associated with ischemia with apoliporotein d
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
HUE050007T2 (hu) 2014-05-16 2020-11-30 Ablynx Nv Immunglobulin variábilis domének
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
AU2015301753B2 (en) 2014-08-12 2021-04-08 Massachusetts Institute Of Technology Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
CN104327187B (zh) * 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
US9920118B2 (en) 2014-10-31 2018-03-20 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
KR102568272B1 (ko) 2015-02-11 2023-08-21 지맥스 바이오팜 엘엘씨 Ｇｌｐ-1ｒ 항체 융합 단백질의 안정한 약제학적 용액 제형
RU2636044C1 (ru) * 2016-05-26 2017-11-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольберга" Средство для стимуляции дифференцировки панкреатических предшественников бета-клеток в продуцирующие и секретирующие инсулин бета-клетки при инсулинзависимом сахарном диабете
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2019060695A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. CHIMERIC POLYPEPTIDES AND USES THEREOF
ES2929416T3 (es) 2018-06-21 2022-11-29 Novo Nordisk As Nuevos compuestos para el tratamiento de la obesidad
CN112771071A (zh) 2018-09-28 2021-05-07 麻省理工学院 胶原蛋白定位的免疫调节分子及其方法
EP3914289A1 (en) 2019-01-23 2021-12-01 Massachusetts Institute of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
DE68929217T2 (de) 1989-03-20 2000-11-30 Gen Hospital Corp Insulinotropes hormon
EP0512042B1 (en) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
DE69838521T2 (de) 1997-07-07 2008-05-21 Medical Research Council Methode zur Erhöhung der Konzentration von Nucleinsäuremolekülen
WO1999007404A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
ATE381939T1 (de) 1997-11-14 2008-01-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
DE69936446T2 (de) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego Inotropische und diuretische effekte von exendin und glp-1
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
NZ555464A (en) * 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
RU2440143C2 (ru) * 2005-09-20 2012-01-20 Новартис Аг Применение ингибитора dpp-iv для снижения приступов гликемии
KR20080077261A (ko) * 2005-12-06 2008-08-21 도만티스 리미티드 Ｅｇｆｒ 및/또는 ｖｅｇｆ에 대해 결합 특이성이 있는리간드 및 그의 사용 방법
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof

Also Published As

Publication number Publication date
US20110020345A1 (en) 2011-01-27
US20130189255A1 (en) 2013-07-25
EP2259802A1 (en) 2010-12-15
AU2009231439A1 (en) 2009-10-08
ZA201006763B (en) 2012-03-28
JP2011517561A (ja) 2011-06-16
CN102046207B (zh) 2013-08-28
BRPI0909397A2 (pt) 2015-12-15
EA018471B1 (ru) 2013-08-30
CN102046207A (zh) 2011-05-04
SG189682A1 (en) 2013-05-31
WO2009121804A1 (en) 2009-10-08
CA2718480A1 (en) 2009-10-08
MX2010010776A (es) 2010-10-26
KR20100132535A (ko) 2010-12-17

Similar Documents

Publication Publication Date Title
EA201001357A1 (ru) Слитые конструкции и конъюгаты лекарственного средства
EA201190184A1 (ru) Продукты слияния и конъюгаты лекарственных средств
EA201290123A1 (ru) Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения
Reguera et al. Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies
CN104066438B (zh) 抗糖尿病化合物
HK1135112A1 (en) Exendin fusion proteins
Wei et al. Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity
ES2335304T3 (es) Uso de polimeros activados para la separacion de multimeros proteicos y polipeptidicos.
PH12016500075B1 (en) Conjugate of biologically active polypeptide monomer and immunoglobulin fc fragment with reduced receptor-mediated clearance, and the method for preparing the same
JP2017008046A5 (ru)
NO20072670L (no) PLAD domene peptider med okt halveringstid i serum pa grunn av konjugering til domene antistoffer
WO2008000516A3 (en) IMPROVED sgp130Fc DIMERS
WO2012040323A3 (en) Multimeric il-15 soluble fusion molecules and methods of making and using same
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
HRP20140258T1 (hr) Bispecifiäśni proteini koji se vežu na antigene
UA87549C2 (en) PREPARATION WHICH CONTAINS the HUMANIZED MONOKLONAL'NOE ANTIBODY 3D6, THAT SPECIFICALLY ZV''YAZUET'SYA From BETA-AMILOIDNIM by PEPTID, And PHARMACEUTICAL PRODUCT
EA201000018A1 (ru) Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения
BRPI0812795C1 (pt) domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso de um domínio ou antagonista de tnfr1, ácido nucleico recombinante, vetor, célula hospedeira, e, composição farmacêutica
ES2668645T3 (es) Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B
Humphreys et al. Alternative antibody Fab′ fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering
RU2016129724A (ru) Антитела, содержащие с-концевые удлинения полипептида легкой цепи, их конъюгаты и способы применения
Gupta et al. Computationally designed antibody–drug conjugates self-assembled via affinity ligands
Kim et al. Pharmacokinetics, pharmacodynamics, and efficacy of a novel long-acting human growth hormone: Fc fusion protein
Wang et al. Multifunctional Antibody Agonists Targeting Glucagon‐like Peptide‐1, Glucagon, and Glucose‐Dependent Insulinotropic Polypeptide Receptors
Ahmadpour et al. PASylation as a powerful technology for improving the pharmacokinetic properties of biopharmaceuticals

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU